

# WIKINGO Project Systematic Analysis

## Tables & Figures.

Proyecto Vikingo

September 29, 2016

`proyectovikingo@proyectovikingo.es`

## Contents

### List of Tables

1	Participant characteristics . . . . .	3
2	According to Local Recurrence . . . . .	4
3	According to Metastasis . . . . .	6
4	According to Exitus . . . . .	8
5	Incidence by outcome [95% CI] . . . . .	13

### List of Figures

1	Local Recurrence . . . . .	5
2	Metastasis . . . . .	7
3	Exitus . . . . .	9
4	Local Recurrence, according to Type of Resection: . . . . .	10
5	Metastasis, according to Type of Resection: . . . . .	11
6	Survival, according to Type of Resection: . . . . .	12

Table 1: Participant characteristics

	[ALL] N=397	N
Age	66.2 (10.9)	397
Sex: Men	246 (62.0%)	397
Tumor level:		397
0-6cm	160 (40.3%)	
7-12cm	196 (49.4%)	
13-15cm	41 (10.3%)	
Tumor stage:		397
0	42 (10.6%)	
I	120 (30.2%)	
II	103 (25.9%)	
III	132 (33.2%)	
Neoadjuvant treatment	288 (72.5%)	397
Type of resection:		397
Abdominoperineal resection	55 (13.9%)	
Anterior resection	317 (79.8%)	
Hartmann	25 (6.30%)	
Perforation	10 (2.52%)	397
Invasion circumferential margin	20 (5.04%)	397
Mesorecto quality:		395
Satisfactory	362 (91.6%)	
Partial	25 (6.33%)	
No-satisfactory	8 (2.03%)	
Recidive	12 (3.02%)	397
Months to recidive	26.0 [9.00;56.0]	397
Metastasis	38 (9.57%)	397
Months to Metastasis	24.0 [9.00;55.0]	397
Exitus	54 (13.6%)	397
Months to exitus	26.0 [9.00;56.0]	397


Table 2: According to Local Recurrence

	No event n= 385	Event n= 12	Crude HR	p-value	Multivariate HR	p-value
Age (10y)	6.61 (1.08)	7.13 (1.31)	1.78 [0.94;3.36]	0.075	2.26 [0.96; 5.29]	0.062
Sex: Men	238 (61.8%)	8 (66.7%)	1.28 [0.39;4.26]	0.686	1.22 [0.30; 4.94]	0.778
Tumor level:						
0-6cm	154 (40.0%)	6 (50.0%)	1.49 [0.18;12.4]	0.712	22.10 [1.34;363.94]	0.03
7-12cm	191 (49.6%)	5 (41.7%)	1.01 [0.12;8.65]	0.993	10.60 [0.86;130.29]	0.065
Tumor stage:						
0	42 (10.9%)	0 (0.00%)	1.00 [0.00;.]	1.000	0.66 [0.00; Inf]	1
II	99 (25.7%)	4 (33.3%)	383356961 [0.00;.]	0.998	184935558.83 [0.00; Inf]	0.998
III	124 (32.2%)	8 (66.7%)	776067808 [0.00;.]	0.998	776324770.64 [0.00; Inf]	0.998
Neoadjuvant treatment	281 (73.0%)	7 (58.3%)	0.44 [0.14;1.40]	0.165	0.76 [0.16; 3.70]	0.738
Type of resection:						
Abdominoperineal resection	53 (13.8%)	2 (16.7%)	1.97 [0.40;9.76]	0.407	0.78 [0.10; 6.34]	0.815
Hartmann	21 (5.45%)	4 (33.3%)	12.3 [3.45;43.8]	<0.001	10.05 [1.97; 51.37]	0.006
Perforation	10 (2.60%)	0 (0.00%)	0.00 [0.00;.]	0.998	0.00 [0.00; Inf]	0.999
Invasion circumferential margin	17 (4.42%)	3 (25.0%)	8.35 [2.23;31.3]	0.002	14.97 [2.48; 90.51]	0.003
Mesorecto quality:						
Partial	24 (6.27%)	1 (8.33%)	4.92 [0.63;38.3]	0.128	2.40 [0.18; 31.54]	0.506
No-satisfactory	8 (2.09%)	0 (0.00%)	0.00 [0.00;.]	0.998	0.00 [0.00; Inf]	0.999

Reference categories:

- Age, a decade
- Sex, Women
- Tumor level, 13-15cm
- Tumor stage: 1
- Neoadjuvant treatment, No
- Type of resection, Anterior resection
- Perforation, No
- Invasion circumferential margin, No
- Mesorecto Quality, Satisfactory

Figure 1: Local Recurrence



Months	0	12	24	36	48	60
N:	397	268	211	172	125	90


Table 3: According to Metastasis

	No event n= 359	Event n= 38	Crude HR	p-value	Multivariate HR	p-value	N
Age (10y)	6.62 (1.10)	6.62 (1.05)	1.06 [0.79;1.42]	0.700	1.36 [0.97; 1.90]	0.072	397
Sex: Men	223 (62.1%)	23 (60.5%)	1.01 [0.53;1.93]	0.982	1.01 [0.51; 1.99]	0.983	397
Tumor level:							397
0-6cm	142 (39.6%)	18 (47.4%)	2.31 [0.54;9.96]	0.262	14.02 [2.32;84.58]	0.004	
7-12cm	178 (49.6%)	18 (47.4%)	1.85 [0.43;7.99]	0.408	12.07 [2.10;69.47]	0.005	
Tumor stage:							397
0	41 (11.4%)	1 (2.63%)	0.83 [0.09;7.40]	0.865	1.03 [0.11; 9.38]	0.979	
II	93 (25.9%)	10 (26.3%)	3.16 [0.99;10.1]	0.052	3.21 [0.99;10.37]	0.052	
III	109 (30.4%)	23 (60.5%)	7.58 [2.61;22.0]	<0.001	8.30 [2.71;25.41]	<0.001	
Neoadjuvant treatment	263 (73.3%)	25 (65.8%)	0.60 [0.31;1.18]	0.137	0.47 [0.22; 1.01]	0.052	397
Type of resection:							397
Abdominoperineal resection	49 (13.6%)	6 (15.8%)	1.18 [0.49;2.84]	0.709	0.74 [0.26; 2.13]	0.576	
Hartmann	23 (6.41%)	2 (5.26%)	1.22 [0.29;5.13]	0.783	0.74 [0.15; 3.51]	0.702	
Perforation	9 (2.51%)	1 (2.63%)	0.83 [0.11;6.06]	0.855	0.13 [0.01; 1.22]	0.074	397
Invasion circumferential margin	13 (3.62%)	7 (18.4%)	6.56 [2.85;15.1]	<0.001	9.67 [3.38;27.68]	<0.001	397
Mesorecto quality:							395
Partial	25 (7.00%)	0 (0.00%)	0.00 [0.00;.]	0.996	0.00 [0.00; Inf]	0.997	
No-satisfactory	7 (1.96%)	1 (2.63%)	0.78 [0.11;5.68]	0.806	0.52 [0.06; 4.28]	0.544	

Reference categories:

- Age, a decade
- Sex, Women
- Tumor level, 13-15cm
- Tumor stage: 1
- Neoadjuvant treatment, No
- Type of resection, Anterior resection
- Perforation, No
- Invasion circumferential margin, No
- Mesorecto Quality, Satisfactory

Figure 2: Metastasis



Months	0	12	24	36	48	60
N:	397	259	195	161	119	85

Table 4: According to Exitus


	No event n= 343	Event n= 54	Crude HR	p-value	Multivariate HR	p-value	N
Age (10y)	6.56 (1.07)	7.03 (1.16)	1.62 [1.21;2.16]	0.001	1.66 [1.20; 2.29]	0.002	397
Sex: Men	214 (62.4%)	32 (59.3%)	0.92 [0.53;1.58]	0.752	0.85 [0.47; 1.53]	0.583	397
Tumor level:							397
0-6cm	136 (39.7%)	24 (44.4%)	0.88 [0.38;2.05]	0.772	4.28 [1.38;13.27]	0.012	
7-12cm	173 (50.4%)	23 (42.6%)	0.69 [0.30;1.62]	0.396	3.17 [1.09; 9.18]	0.034	
Tumor stage:							397
0	41 (12.0%)	1 (1.85%)	0.28 [0.04;2.17]	0.223	0.43 [0.06; 3.39]	0.425	
II	90 (26.2%)	13 (24.1%)	1.37 [0.62;2.99]	0.436	1.32 [0.60; 2.93]	0.492	
III	104 (30.3%)	28 (51.9%)	3.04 [1.54;5.99]	0.001	3.39 [1.60; 7.17]	0.001	
Neoadjuvant treatment	259 (75.5%)	29 (53.7%)	0.35 [0.20;0.60]	<0.001	0.43 [0.23; 0.81]	0.009	397
Type of resection:							397
Abdominoperineal resection	47 (13.7%)	8 (14.8%)	1.31 [0.61;2.80]	0.491	0.92 [0.37; 2.32]	0.864	
Hartmann	17 (4.96%)	8 (14.8%)	4.37 [2.03;9.40]	<0.001	2.94 [1.27; 6.82]	0.012	
Perforation	8 (2.33%)	2 (3.70%)	1.19 [0.29;4.87]	0.812	0.36 [0.07; 1.83]	0.217	397
Invasion circumferential margin	12 (3.50%)	8 (14.8%)	5.41 [2.53;11.6]	<0.001	5.16 [1.96;13.54]	<0.001	397
Mesorecto quality:							395
Partial	24 (7.02%)	1 (1.89%)	0.90 [0.12;6.52]	0.914	0.50 [0.06; 3.90]	0.508	
No-satisfactory	6 (1.75%)	2 (3.77%)	1.18 [0.29;4.84]	0.822	0.82 [0.18; 3.75]	0.798	

Reference categories:

- Age, a decade
- Sex, Women
- Tumor level, 13-15cm
- Tumor stage: 1
- Neoadjuvant treatment, No
- Type of resection, Anterior resection
- Perforation, No
- Invasion circumferential margin, No
- Mesorecto Quality, Satisfactory




Figure 3: Exitus




Months	0	12	24	36	48	60
N:	397	270	212	173	126	90

Figure 4: Local Recurrence, according to Type of Resection:




Tiempo	0	12	24	36	48	60
Abd	55	40	31	24	16	10
Ant	317	232	177	148	119	77
H	25	15	9	5	4	3

Figure 5: Metastasis, according to Type of Resection:



Tiempo	0	12	24	36	48	60
Abd	55	38	29	24	16	9
Ant	317	228	164	136	114	73
H	25	13	8	5	4	3

Figure 6: Survival, according to Type of Resection:



Tiempo	0	12	24	36	48	60
Abd	55	40	32	24	16	10
Ant	317	233	177	149	120	77
H	25	15	9	5	4	3

Table 5: Incidence by outcome [95% CI]

Months	Local Recurrence	Metastasis	Exitus
12	1.34 [2.64; 0.03]	4.55 [6.86; 2.19]	2.71 [4.46; 0.94]
24	3.43 [5.63; 1.18]	9.57 [13.05; 5.95]	8.24 [11.46; 4.91]
36	4.45 [7.02; 1.81]	13.52 [17.74; 9.09]	13.32 [17.48; 8.96]
48	5.08 [7.9; 2.17]	15.31 [19.86; 10.49]	21.29 [26.56; 15.65]
60	5.08 [7.9; 2.17]	16.24 [21.07; 11.11]	24.95 [30.78; 18.62]